

***Fiscal Year 2024 Department of Defense Neurofibromatosis Research Program (NFRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Neurofibromatosis Research Academy – Leadership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524NFRPNFRALA</p>	<ul style="list-style-type: none"> • Academy Director - must be an independent and established neurofibromatosis (NF) investigator at or above the level of Associate Professor (or equivalent) as of the full application submission deadline. • Deputy Director - must be an independent NF researcher at the level of Associate Professor (or equivalent) as of the full application submission deadline and at a different institution from the Director. • Both the Director and the Deputy Director are required to commit a minimum of 10% effort each during the first year and 20% each in subsequent years. 	<ul style="list-style-type: none"> • Pre-application submission is required; application submission is by invitation only. • Supports the establishment and management of a multi-institutional, interactive, virtual research academy that consists of Scholars (early-career investigators) and their Career Guides (primary mentors) from different institutions under the leadership of an Academy Director and Deputy Director to foster collaborative research and career development. • Must have vision and plan of how the leadership team will help Academy Scholars to advance research and promote development as next generation of NF leaders. • Leadership/support, network opportunities, management and communication plans for the Academy must be clearly articulated. • Supports visionary individuals who are established NF researchers with a strong record of mentoring and commitment to leadership. • Academy leadership (Director and Deputy Director) <u>must have past publication records</u> in peer-reviewed journals and past and/or present research funding. • Clinical trials are <u>not</u> allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.5 million (M) for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 5 years. 	<p>Pre-Application (Letter of Intent): August 22, 2024 5:00 p.m. Eastern time (ET)</p> <p>Application: September 12, 2024 11:59 p.m. ET</p> <p>Oral Presentation: January 2025 5:00 p.m. ET</p>
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524NFRPCTA</p>	<p>Investigators must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Submission of a Letter of Intent is required prior to full application submission. • Supports phase 0, 1, or 2 clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted. • Funding must support a clinical trial and may not be used for preclinical studies. • Scientific rationale and preliminary data are required for phase 1 and 2 clinical trial applications. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. • Maximum funding of \$1.0M for direct costs for applications including a Collaborator. • Indirect costs may be proposed in accordance 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
			with the institution’s negotiated rate agreement. <ul style="list-style-type: none"> The maximum period of performance is 4 years. 	
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524NFRPEIRA</p>	<ul style="list-style-type: none"> Investigators must be involved in a postdoctoral training or medical residency program and possess up to 4 years continuous postdoctoral research experience. Investigators must have successfully defended a doctoral thesis or possess an M.D. degree and <i>commit a minimum of 50% of their effort</i> towards the project. 	<ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Supports research focused on NF for individuals in the early stages of their careers. Investigators must have a designated mentor who is an experienced NF researcher. Clinical trials are <u>not</u> allowed. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$200,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p> <p>Confidential Letters of Recommendation: October 10, 2024 5:00 p.m. ET</p>
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524NFRPEHDA</p>	<p>Investigators may be from all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Projects involving human subjects or human biological substances must be exempt under the Code of Federal Regulations, Title 32, Section 219, Part 104(d) (32 CFR 219.104[d]) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. Preliminary and/or published data are encouraged but not required. Mentorship is highly encouraged. Clinical trials are <u>not</u> allowed. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$100,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524NFRPIIRA</p>	<p>Investigators must be at or above the level of Assistant Professor (or equivalent) and must plan to <i>commit a minimum of 10% level of effort</i> for each budget period throughout the entirety of the award.</p>	<ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Optional Features: Applications meeting the criteria identified in the announcement may apply for a higher level of funding for the following options: <ul style="list-style-type: none"> Qualified Collaborator. NF Open Science Initiative. Preliminary and/or published data are required. Clinical trials are <u>not</u> allowed. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$525,000 for direct costs. Maximum funding of \$575,000 for direct costs for applications including either an Optional Qualified Collaborator or a Data Sharing Option. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p>
<p>New Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524NFRPNIA</p>	<ul style="list-style-type: none"> Early-Stage Investigator (ESI): An independent investigator who is at or below the level of Assistant Professor (or equivalent) and able to <i>commit a minimum of 30% level of effort</i> during each budget year of their efforts toward the proposed NF research project. Established Investigator (EI): An independent investigator who is above the level of Assistant Professor and able to <i>commit a minimum of 10% level of effort</i> during each budget year of their efforts toward the proposed NF research project. 	<ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. ESI: Supports research conducted by promising independent investigators. EI: Supports research conducted by independent investigators who will transition from other research fields. The investigator will bring their expertise into a career in the field of NF research. Experience in NF research is allowed, but not required. Preliminary and/or published data are required. Must not have received a New Investigator Award previously from any program within the CDMRP. Clinical trials are <u>not</u> allowed. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$450,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Synergistic Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524NFRPSIA</p>	<p>Investigators must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Submission of a Letter of Intent is required prior to full application submission. • Supports new or existing partnerships between <u>two or three investigators</u> to address a central innovative question or problem in NF that may include high risk, provided there is a potential for significant impact. • Investigators are expected to demonstrate the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through the independent efforts of a single investigator. • <i>Preliminary and/or published data are required.</i> • Synergy, Research Strategy, Personnel, and Impact are the most important review criteria. • Clinical trials are <u>not</u> allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0M for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p>